(USD) | Mar 2024 | Q/Q |
---|---|---|
Revenue | 3.2B | -48% |
Gross Profit | 897.3MM | -46% |
Cost Of Revenue | 2.3B | -48% |
Operating Income | 321.3MM | +55% |
Operating Expenses | 576MM | - |
Net Income | 228MM | - |
G&A | 508.4MM | -49% |
Amortization | 60.1MM | -47% |
Interest Expense | 46.9MM | -53% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
On April 29, 2024, Peter Wilkinson, Senior Vice President and Chief Accounting Officer at Laboratory Corp of America Holdings (NYSE:LH), sold 2,439 shares of the company.
Insightful Analysis of LH's Market Position and Future Prospects
Laboratory Corporation of America Holdings (NYSE:LH) Q1 2024 Earnings Call Transcript April 25, 2024 Laboratory Corporation of America Holdings beats earnings expectations. Reported EPS is $3.68, expectations were $3.46. Laboratory Corporation of America Holdings isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details […]
The board of Laboratory Corporation of America Holdings ( NYSE:LH ) has announced that it will pay a dividend on the...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy.
Integer Holdings' (ITGR) first-quarter results reflect robust Medical Sales, along with strength in all the product lines.
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Laboratory Corporation of America Holdings ( NYSE:LH ) First Quarter 2024 Results Key Financial Results Revenue...